
A team led by Daniel Monti, MD, who is the director of the Myrna Brind Center of Integrative Medicine at Thomas Jefferson, plans to enroll twenty patients for whom standard non-Hodgkin lymphoma therapy has been unsuccessful. Trial participants will receive varying doses of intravenous vitamin C three times per week while being monitored for disease progression. Continue Reading
No comments:
Post a Comment